BR112022012821A2 - Agente de ligação a ccr5 para tratamento de câncer metastático positivo para ccr5 - Google Patents

Agente de ligação a ccr5 para tratamento de câncer metastático positivo para ccr5

Info

Publication number
BR112022012821A2
BR112022012821A2 BR112022012821A BR112022012821A BR112022012821A2 BR 112022012821 A2 BR112022012821 A2 BR 112022012821A2 BR 112022012821 A BR112022012821 A BR 112022012821A BR 112022012821 A BR112022012821 A BR 112022012821A BR 112022012821 A2 BR112022012821 A2 BR 112022012821A2
Authority
BR
Brazil
Prior art keywords
ccr5
treatment
binding agent
metastatic cancer
positive metastatic
Prior art date
Application number
BR112022012821A
Other languages
English (en)
Inventor
Kelly Scott
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of BR112022012821A2 publication Critical patent/BR112022012821A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

AGENTE DE LIGAÇÃO A CCR5 PARA TRATAMENTO DE CÂNCER METASTÁTICO POSITIVO PARA CCR5. A presente divulgação refere-se ao uso de agentes de ligação a CCR5, tal como o leronlimab, no tratamento ou prevenção de câncer metastático CCR5+. Neste documento são apresentados métodos para tratar um indivíduo com câncer de mama metastático pela administração ao indivíduo de uma quantidade eficaz de um agente de ligação a CCR5, tal como leronlimab.
BR112022012821A 2020-01-13 2021-01-13 Agente de ligação a ccr5 para tratamento de câncer metastático positivo para ccr5 BR112022012821A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062960613P 2020-01-13 2020-01-13
US202062968954P 2020-01-31 2020-01-31
US202062977023P 2020-02-14 2020-02-14
PCT/US2021/013289 WO2021146323A1 (en) 2020-01-13 2021-01-13 Ccr5 binding agent for treatment of ccr5 positive metastatic breast cancer

Publications (1)

Publication Number Publication Date
BR112022012821A2 true BR112022012821A2 (pt) 2022-12-13

Family

ID=76760851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012821A BR112022012821A2 (pt) 2020-01-13 2021-01-13 Agente de ligação a ccr5 para tratamento de câncer metastático positivo para ccr5

Country Status (11)

Country Link
US (1) US20210214448A1 (pt)
EP (1) EP4090675A4 (pt)
JP (1) JP2023511277A (pt)
KR (1) KR20220127859A (pt)
CN (1) CN115003691A (pt)
AU (1) AU2021207851A1 (pt)
BR (1) BR112022012821A2 (pt)
CA (1) CA3163060A1 (pt)
IL (1) IL294113A (pt)
MX (1) MX2022008632A (pt)
WO (1) WO2021146323A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947431A4 (en) * 2019-04-01 2022-12-28 CytoDyn Inc. ANTI-CCR5 AGENTS AND TREATMENT METHODS TO BLOCK CANCER METASTASIS OR INCREASE CELL DEATH INDUCED BY DNA-DAMAGING CHEMOTHERAPY

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217674C1 (en) * 2002-02-22 2009-03-26 Abbvie Biotherapeutics Inc. Anti-CCR5 antibody
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US9453836B2 (en) * 2012-05-14 2016-09-27 Richard G. Pestell Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
JP2017517506A (ja) * 2014-05-21 2017-06-29 ファイザー・インコーポレイテッド 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用
AU2015343339A1 (en) * 2014-11-03 2017-06-15 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
EP3313412A4 (en) * 2015-06-23 2019-01-16 CytoDyn Inc. CCL5 LIGAND BINDING INHIBITION TO CCR5 RECEPTOR AND CCR5 / CCL5 AXIS SIGNALING MODIFICATION IN INFLAMMATION, CANCER, AUTOIMMUNIT DISEASE OR OTHER CONDITIONS
ES2850428T3 (es) * 2016-04-15 2021-08-30 Hoffmann La Roche Procedimientos de monitorización y tratamiento del cáncer
KR20190075114A (ko) * 2016-11-04 2019-06-28 제넨테크, 인크. Her2-양성 유방암의 치료
CN111886249A (zh) * 2017-09-18 2020-11-03 西托戴恩股份有限公司 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法
WO2019195409A1 (en) * 2018-04-03 2019-10-10 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
WO2020009988A1 (en) * 2018-07-02 2020-01-09 Incelldx, Inc. Methods for detecting cancer-related cell populations, screening for metastatic cancer and treatments thereof
EP3947431A4 (en) * 2019-04-01 2022-12-28 CytoDyn Inc. ANTI-CCR5 AGENTS AND TREATMENT METHODS TO BLOCK CANCER METASTASIS OR INCREASE CELL DEATH INDUCED BY DNA-DAMAGING CHEMOTHERAPY

Also Published As

Publication number Publication date
AU2021207851A1 (en) 2022-07-14
WO2021146323A9 (en) 2021-08-26
US20210214448A1 (en) 2021-07-15
EP4090675A4 (en) 2024-02-21
MX2022008632A (es) 2022-08-08
KR20220127859A (ko) 2022-09-20
JP2023511277A (ja) 2023-03-17
CA3163060A1 (en) 2021-07-22
EP4090675A1 (en) 2022-11-23
CN115003691A (zh) 2022-09-02
IL294113A (en) 2022-08-01
WO2021146323A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2023003470A (es) Anticuerpo anti-garp.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
MX2016007351A (es) Terapia de combinacion para tratar cancer.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
NZ729643A (en) Combination therapy for treating cancer
BR112015033053A2 (pt) método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112022001341A2 (pt) Inibidores de enzima
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
PH12021550832A1 (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
BR112016023011A2 (pt) tratamento de câncer gástrico
BR112022012821A2 (pt) Agente de ligação a ccr5 para tratamento de câncer metastático positivo para ccr5
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.